Pantelis Vlachos

Cytel announces East Alloy for easy access to verified Bayesian methods

Cytel Inc., an advanced analytics leader providing sophisticated quantitative insights to decision-makers in clinical investigation, has launched East Alloy. This new platform is a web-native extension of Cytel’s world-renowned East software for adaptive clinical trial design and analysis.
By leveraging the speed of cloud computing and the pace of SaaS delivery, East Alloy enables easy implementation of computationally intensive Bayesian methods that may be otherwise impractical. The launch of East Alloy builds on Cytel’s time-tested record of delivering cutting-edge Bayesian tools and engines to the pharmaceutical industry for optimized clinical trials.
Bayesian methods are of growing interest to the drug development industry, as they allow clinical investigators to leverage historical trial data as well as learnings from new data as it accrues throughout a trial. The result is better-informed decision making, greater program flexibility, and the ability to run smaller, more resource-efficient trials.
“Our longstanding dedication to adaptive Bayesian approaches means we’re perfectly placed to meet and exceed the growing innovation needs of the pharmaceutical sector,” said Pantelis Vlachos, Director and Strategic Consultant at Cytel. “But it’s key to ensure our customers can practically implement this kind of innovation. East Alloy, reinforced by industry-leading verification, training, and support from Cytel experts, means users can sustainably adopt Bayesian designs to expedite clinical development and overcome uncertainty without compromising scientific rigor.”
The release of East Alloy follows the launch of East Hosted in 2019, which brought Cytel’s East software into the cloud for the first time to simplify the deployment of software updates, reduce on-premise IT burden, and ultimately broaden access to Cytel’s trial design and analysis engines.

  • For more information about Cytel, visit: https://www.cytel.com

Read more

porvairpr549

Porvair introduces stackable, low profile deep well microplates for lab automation

Porvair Sciences has introduced a new range of low profile deep well microplates – optimised for laboratory automation.
Flexibility, scalability and efficient use of storage space is essential to productive automation workflows. This new range of 96-well deep well microplates are designed to maximise storage space by offering a storage volume of 0.5 ml / well in a reduced plate height of just 27 mm.
This new low profile design allows more plates to be stored or stacked in a given space. Combining an affordable price with uncompromising high quality, Porvair low profile 0.5 ml deep well plates are precisely manufactured to comply with ANSI/SLAS dimensions ensuring complete compatibility with all manual and automated sample handling systems, microplate readers and washers.
Available sterile or non-sterile, Porvair low profile 96-well deep well plates are manufactured from RNase / DNase-free, low leachables polypropylene that undergoes extensive quality testing to ensure a product of the highest quality. Offering high chemical and temperature resistance (-196 °C to +121 °C) the design of these autoclavable low profile plates includes a U-bottom to enable maximum liquid uptake, alphanumeric well coding for easy sample tracking and raised well rims to enable easy, high integrity sealing.

  • For further information, visit https://www.microplates.com/low-profile-96-well-plates/ or for a free sample plate contact Porvair Sciences: enquiries@porvairsciences.com

Read more

ErbaLisa COVID 19 IgG box out VII

Making SARS-CoV-2 testing available to labs everywhere

As COVID-19 multiplied across the globe in early 2020, IVD companies raced to provide testing solutions. However, rapid development of diagnostic solutions led in some cases to compromised reagent quality, causing confusion and concern amongst clinicians and lab professionals.
With this background, Erba Mannheim committed to develop reliable and affordable solutions to SARS-CoV-2 testing. First out have been the ErbaLisa IgG and IgM antibody ELISA kits. These were developed and manufactured by Calbiotech, Erba group’s immunoassay center of excellence in California.
Quality and performance were top priorities. The IgG kits use Spike protein antigens to ensure clinical relevance and specificity, and IgM kits use a combination of Spike and Nucleocapsid antigens. Performance and accuracy were extensively validated by multiple studies in universities and public/private laboratories. With CE mark and pending US EUA authorization, ErbaLisa COVID-19 assays gained approval by strict global regulatory bodies including Brazil’s ANVISA and ICMR in India.
Our commitment is to make quality diagnostic solutions affordable to growing labs across all emerging markets in Asia, LATAM, MEA, Eastern Europe and Russia. We believe these products answer the immediate needs and are proud to be helping in the fight against COVID-19.
Read more

C170 Bontkes fig1

Serological biomarkers for refractory celiac disease

by Dr Hetty J. Bontkes

Type II refractory celiac disease (RCD-II) and enteropathy associated T-cell lymphoma (EATL) are rare but serious complications of adult onset celiac disease.

 

Read more

Medlab Asia

October 28-30, 2020
Bangkok, Asia
www.medlabasia.com

DxFLEX

(OLD) DxFLEX – Gain independent compensation

Two types of photon detectors are used to amplify and then convert lightinto electronic signals in flow cytometry. The traditional detector is the photomultiplier tube (PMT). Avalanche Photodiodes (APD) are another type of photon detector and are used in the DxFLEX flow cytometer.

clinical webinars

Nova Biomedical to Host Webinar on COVID-19 Bedside Glucose Management

Waltham, MA–Nova Biomedical to host “COVID-19 Bedside Glucose Management: Risk of Ascorbic Acid and Hematocrit Interference,” a webinar led by Charbel Abou-Diwan, PhD, Director of Medical and Scientific Affairs, to help inform and support healthcare workers treating COVID-19 patients.

Critical-Thinking-for-Early-Diagnosis-of-Prostate-Cancer

(OLD) Critical Thinking for Early Diagnosis of Prostate Cancer

The best outcomes in cancer treatment can be achieved with early diagnosis. Prostate-specific antigen (PSA) is unique in that it is the only tissue-specific biomarker that can aid in the early diagnosis…